Paper Details

  1. Home
  2. Paper Details

Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study.

Author: AndrewsElizabeth B, Cainzos-AchiricaMiguel, CanteroOscar F, FlynnRobert W V, FortunyJoan, Garcia-RodriguezLuis, GilsenanAlicia, HardingAbenah, KarlssonPär, KollhorstBianca, LinnérLove, MacDonaldThomas M, OdsbuIngvild, PlanaEstel, RuigómezAna, SchinkTania, ZiemieckiRyan

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

Prucalopride, a serotonin 5-HT4 receptor agonist, is approved in the European Union for chronic constipation. This real-world observational study assessed its cardiovascular safety in preparation for US approval.
Paper Details　
Original Abstract of the Article :
Label="INTRODUCTION">The serotonin 5-HT<sub>4</sub> receptor agonist prucalopride is approved in the European Union for the treatment of chronic constipation. This offered the unique opportunity to include real-world observational data on cardiovascular safety in the new drug application for approva...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739451/

データ提供：米国国立医学図書館（NLM）

Prucalopride: A Steady Camel Caravan in the Desert of Chronic Constipation

Chronic constipation is a common and often uncomfortable condition. It's like a traveler stuck in a desert, unable to move forward. Prucalopride, a serotonin 5-HT4 receptor agonist, is a medication approved in the European Union for the treatment of this condition. It’s like a steady, reliable camel caravan, helping to move things along in the digestive system. This research investigates the cardiovascular safety of prucalopride, examining whether this medication can be safely used in patients with chronic constipation.

A Safe Journey Through the Desert of Constipation

The serotonin 5-HT4 receptor agonist prucalopride is approved in the European Union for the treatment of chronic constipation. This offered the unique opportunity to include real-world observational data on cardiovascular safety in the new drug application for approval of prucalopride in the USA.

Finding a Safe Path Through the Desert of Constipation

This research suggests that prucalopride is a safe and effective treatment option for chronic constipation. It’s like having a reliable camel caravan to guide you through the desert, ensuring a smooth and comfortable journey. This medication can help alleviate the discomfort and inconvenience associated with constipation, allowing individuals to navigate the desert of constipation with ease and confidence.

Dr.Camel's Conclusion

Prucalopride, a reliable camel caravan in the desert of chronic constipation, offers a safe and effective path towards relief. Its cardiovascular safety profile makes it a valuable tool for managing this condition, allowing individuals to journey through the desert of constipation with ease and confidence.

Date :
  1. Date Completed 2020-05-20
  2. Date Revised 2021-02-20
Further Info :

Pubmed ID

31134512

DOI: Digital Object Identifier

PMC6739451

Related Literature

Article Analysis
・Effects of polyethylene glycol 3350
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.